Surrozen

SRZN

시가총액 US$2.76억

First patient expected to be dosed in the DUET study in the fourth quarter of 2026 Milestone triggers second closing of March 2025 private placement expected to provide approximately $95.1M in gross proceeds SOUTH SAN FRANCISCO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced its Investigational New Drug (IND) application for SZN-8141 has become effective, enabling the Company to advance the program into clinical development.

Surrozen Inc. (NASDAQ:SRZN) skyrocketed on Thursday after the company submitted an Investigational New Drug application to the U.S. Food and Drug Administration to evaluate SZN-8141 for treating diabetic macular edema.

Surrozen, Inc. (SRZN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration seeking to evaluate SZN-8141, a bifunctional Wnt agonist and vascular endothelial growth factor (VEGF) antagonist antibody, for the treatment of diabetic macular edema (DME).

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at two upcoming healthcare investor conferences.

Planned IND submission for SZN-8141 in diabetic macular edema by the end of the third quarter of 2026 Expect to initiate SZN-8141 Phase 1b/2a study, DUET, by year-end 2026 with initial data anticipated in the second half of 2027 U.S. Patent Trial and Appeal Board denies institution of post-grant review petition challenging Surrozen patent SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced financial results for the second quarter ended June 30, 2026 and provided a business update.

Surrozen NASDAQ: SRZN Chief Executive Officer Craig Parker outlined the company's rationale for developing Wnt-targeting retinal disease therapies during H.C. Wainwright's 6th Annual Ophthalmology Investor Conference, emphasizing the company's focus on Frizzled-4 signaling, anti-VEGF activity and, in one preclinical program, IL-6 inhibition.

Surrozen to Present at Upcoming Healthcare Investor Conference: H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on Wednesday, July 22, 2026

SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference.

On track to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026 Well-capitalized with $106.9 million in cash and cash equivalents as of March 31, 2026 SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced financial results for the first quarter ended March 31, 2026 and provided a business update.